All stock lists
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
3.59-0.29 (-7.47%)
Market cap
$217M
Insider Score
Health Score
Analyst consensus
Listed since
Apr 12, 2006
Website
Insider Score
92/ 100
VNDA Insider Score
Bullish3 qualifying trades · 1 insider · $38.09K bought in the last 90 days
Financial Health Score
Weak
From VNDA’s reported statements · Q3 2026 (trailing 12 months)
Profitability0 / 20
Loses money on what it sells.
- Revenue
- $229.3M
- Net income
- -$274.8M
- Net margin
- -119.9%
Leverage19 / 20
Little or no net debt.
- Total debt
- $22.0M
- Cash
- $61.9M
- Debt / equity
- 0.11
Liquidity14 / 20
Comfortably covers what is due within a year.
- Current assets
- $238.5M
- Current liabilities
- $155.0M
- Current ratio
- 1.54
Cash generation0 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$189.4M
- Free cash flow
- -$190.4M
- FCF margin
- -83.0%
Dilution & runway0 / 20
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 60.5M
- Share growth (1y)
- 2.7%
- Cash runway
- 4 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
VNDA Income Statement
| Fiscal Period | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | 69.81 M | 50.53 M | 51.72 M | 57.22 M | 56.26 M | 52.59 M |
| Revenue Growth (YoY) | 24.10 % | -3.92 % | 3.35 % | 7.58 % | 18.06 % | 4.19 % |
| Cost of Revenue | 4.15 M | 3.56 M | 5.15 M | 3.83 M | 2.95 M | 4.49 M |
| Gross Profit | 65.66 M | 46.97 M | 46.57 M | 53.38 M | 53.30 M | 48.10 M |
| SG&A Expense | 59.58 M | 71.84 M | 68.36 M | 62.98 M | 60.27 M | 64.62 M |
| R&D Expense | 27.62 M | 36.95 M | 28.43 M | 29.01 M | 22.56 M | 21.99 M |
| Operating Expenses | 89.18 M | 110.78 M | 96.80 M | 93.74 M | 84.59 M | 86.61 M |
| Operating Income | -23.52 M | -63.81 M | -50.22 M | -40.35 M | -31.28 M | -38.50 M |
| Pretax Income | -22.39 M | -62.38 M | -48.42 M | -38.00 M | -28.39 M | -34.89 M |
| Tax Provision | 174.00 K | 129.00 K | 143.00 K | 103.19 M | -5.80 M | -7.68 M |
| Net Income | -22.56 M | -62.51 M | -48.57 M | -141.19 M | -22.59 M | -27.21 M |
| EPS (Basic) | -0.37 | -1.04 | -0.82 | -2.39 | -0.38 | -0.46 |
| EPS (Diluted) | -0.37 | -1.04 | -0.82 | -2.39 | -0.38 | -0.46 |
| Shares Outstanding | 60.47 M | 60.23 M | 59.46 M | 59.10 M | 58.87 M | 58.99 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.